Physician profile

James Foster

Medical · Oklahoma City, OK

NPI 1912943747

$498.53

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$22.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $162.15 2021
Abbvie INC. $122.59 2021-2022
Sunovion Pharmaceuticals INC. $50.16 2021-2022
Boehringer Ingelheim Pharmaceuticals, INC. $40.45 2021
Lilly USA, LLC $38.06 2021-2023 Jardiance
Amarin Pharma, INC. $26.83 2021
Virtus Pharmaceuticals LLC $19.43 2021
Vanda Pharmaceuticals INC. $14.60 2021
Glaxosmithkline, LLC. $13.12 2021
Novartis Pharmaceuticals Corporation $11.14 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Foster

$498.53

in general payments reported 2019-2025

Years
2021-2023
Top company
Novo Nordisk INC

https://glasscript.com/doctor/816305/james-foster

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.